USA flag logo/image

An Official Website of the United States Government

Radiation Protection Cancer Therapy with an SOD Mimetic

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
65364
Program Year/Program:
2003 / SBIR
Agency Tracking Number:
CA096245
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
AEOLUS PHARMACEUTICALS, INC.
AEOLUS PHARMACEUTICALS, INC. 26361 Crown Valley Parkway, Suite 150 Mission Viejo, CA 92694
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2003
Title: Radiation Protection Cancer Therapy with an SOD Mimetic
Agency: HHS
Contract: 1R44CA096245-01A2
Award Amount: $100,000.00
 

Abstract:

DESCRIPTION (provided by applicant): Phase I. In the treatment of cancer, radiation therapy has been limited by the tolerance of the surrounding normal tissues, such as lung or mucosa. Until now, there have been no compounds available that protect the normal tissues without reducing the tumor response to radiation therapy. The overall goal of this project is to develop a new approach to radiation therapy for cancer, based on the recently discovered radioprotective effects of novel synthetic catalytic SOD mimetic compounds. These compounds may also independently inhibit tumor growth under certain conditions. In Phase 1 of this SBIR application specific SOD mimetics will have demonstrated effectiveness in animal models of radiation therapy of human cancers. The proposed study will specifically research a selected compound in preparation for human studies directed at enhancing the efficacy of radiation therapy. The goal is to both increase tolerance of normal tissues to radiation therapy and retain or increase the net anti-tumor effects. Well-established functional, radiographic and histopathologic end-points will be used to assess possible mechanisms behind this compound's radioprotective effect in rat and hamster models of radiation-induced injury. Models of both radiation-induced mucositis and radiation-induced lung fibrosis will be studied. The antitumor effect of the selected SOD mimetic given alone or in combination with radiation therapy will be evaluated by using standard tumor growth delay assays. This new strategy of utilizing a single compound with both anti-tumor and radioprotective properties in combination with radiotherapy could result in an improvement in patient survival with a concomitant reduction in the risk of complications. The potential of independent tumor growth inhibition by the SOD mimetics would be an additional benefit.

Principal Investigator:

Richard E. Gammans
9195581931
RGAMMANS@INCARA.COM

Business Contact:


9195581908
Small Business Information at Submission:

INCARA PHARMACEUTICALS CORPORATION
INCARA PHARMACEUTICALS CORPORATION BOX 14287, 79 TW ALEXANDER DR RESEARCH TRIANGLE PARK, NC 27709

EIN/Tax ID: 561924222
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No